MISSISSAUGA, Ontario (AP) _ Trillium Therapeutics Inc. (TRIL) on Friday reported a loss of $19.3 million in its third quarter.
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage...
CAMBRIDGE, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage...
Big money is pouring into two disruptive segments in two of the world’s biggest industries - ...
A massive disruption now appears imminent in one of the world’s largest – and most important ...
TORONTO — Some of the most active companies traded Monday on the Toronto Stock Exchange:
TORONTO — Trillium Therapeutics Inc. has signed a deal to be bought by Pfizer Inc. in an agreement valued at US$2.26 billion.
Pfizer Inc. (NYSE: PFE) and Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Trillium, a clinical...
Proposed acquisition strengthens Pfizer’s category leadership in Oncology with addition of next-generation, investigational immuno-therapeutics for hematological malignancies
CAMBRIDGE, Mass., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,...